{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:08:21Z","timestamp":1785434901906,"version":"3.56.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00210-021-02130-1","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T04:02:31Z","timestamp":1629086551000},"page":"2117-2128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4"],"prefix":"10.1007","volume":"394","author":[{"given":"Rasha M. S. M.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa M.","family":"Elshazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola E.","family":"Nafea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia M.","family":"Abd El Motteleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"2130_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.vph.2015.05.008","volume":"74","author":"P Abeyrathna","year":"2015","unstructured":"Abeyrathna P, Su Y (2015) The critical role of Akt in cardiovascular function. Vascul Pharmacol 74:38\u201348. https:\/\/doi.org\/10.1016\/j.vph.2015.05.008","journal-title":"Vascul Pharmacol"},{"key":"2130_CR2","doi-asserted-by":"publisher","first-page":"e37840","DOI":"10.5812\/numonthly.37840","volume":"8","author":"H Askari","year":"2016","unstructured":"Askari H, Seifi B, Kadkhodaee M (2016) Evaluation of renal-hepatic functional indices and blood pressure based on the progress of time in a rat model of chronic kidney disease. Nephrourol Mon 8:e37840. https:\/\/doi.org\/10.5812\/numonthly.37840","journal-title":"Nephrourol Mon"},{"key":"2130_CR3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","volume":"70","author":"GL Bakris","year":"2006","unstructured":"Bakris GL, Hart P, Ritz E (2006) Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905\u20131913. https:\/\/doi.org\/10.1038\/sj.ki.5001835","journal-title":"Kidney Int"},{"key":"2130_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1161\/HYPERTENSIONAHA.113.02043","volume":"63","author":"A Bathgate-Siryk","year":"2014","unstructured":"Bathgate-Siryk A, Dabul S, Pandya K, Walklett K, Rengo G, Cannavo A, De Lucia C, Liccardo D, Gao E, Leosco D, Koch WJ, Lymperopoulos A (2014) Negative impact of \u03b2-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 63:404\u2013412. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02043","journal-title":"Hypertension"},{"key":"2130_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/joim.12818","volume":"285","author":"M Carlstrom","year":"2019","unstructured":"Carlstrom M, Montenegro MF (2019) Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease. J Intern Med 285:2\u201318. https:\/\/doi.org\/10.1111\/joim.12818","journal-title":"J Intern Med"},{"key":"2130_CR6","doi-asserted-by":"publisher","first-page":"f55","DOI":"10.1136\/bmj.f55","volume":"346","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Biondi-Zoccai G, Abbate A, D\u2019Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013) Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346:f55\u2013f55. https:\/\/doi.org\/10.1136\/bmj.f55","journal-title":"BMJ"},{"key":"2130_CR7","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","volume":"41","author":"G Cice","year":"2003","unstructured":"Cice G, Ferrara L, D\u2019Andrea A, D\u2019Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabr\u00f2 R (2003) Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 41:1438\u20131444. https:\/\/doi.org\/10.1016\/S0735-1097(03)00241-9","journal-title":"J Am Coll Cardiol"},{"key":"2130_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0735-1097(00)01158-X","volume":"37","author":"G Cice","year":"2001","unstructured":"Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A (2001) Dilated cardiomyopathy in dialysis patients\u2014beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 37:407\u2013411. https:\/\/doi.org\/10.1016\/S0735-1097(00)01158-X","journal-title":"J Am Coll Cardiol"},{"key":"2130_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000356369","volume":"36","author":"A Clementi","year":"2013","unstructured":"Clementi A, Virz\u00ec GM, Brocca A, de Cal M, Vescovo G, Granata A, Ronco C (2013a) Cardiorenal syndrome type 4: management. Blood Purif 36:200\u2013209. https:\/\/doi.org\/10.1159\/000356369","journal-title":"Blood Purif"},{"key":"2130_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000350397","volume":"3","author":"A Clementi","year":"2013","unstructured":"Clementi A, Virz\u00ec GM, Goh CY, Cruz DN, Granata A, Vescovo G, Ronco C (2013b) Cardiorenal syndrome type 4: a review. Cardiorenal Med 3:63\u201370. https:\/\/doi.org\/10.1159\/000350397","journal-title":"Cardiorenal Med"},{"key":"2130_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0195-668X(03)00476-7","volume":"24","author":"M Cowie","year":"2003","unstructured":"Cowie M (2003) Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24:1710\u20131718. https:\/\/doi.org\/10.1016\/S0195-668X(03)00476-7","journal-title":"Eur Heart J"},{"key":"2130_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1586\/14779072.5.1.21","volume":"5","author":"RN Doughty","year":"2007","unstructured":"Doughty RN, White HD (2007) Carvedilol: use in chronic heart failure. Expert Rev Cardiovasc Ther 5:21\u201331. https:\/\/doi.org\/10.1586\/14779072.5.1.21","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2130_CR13","doi-asserted-by":"publisher","unstructured":"Esmaeeli A, Keshavarz Z, Dehdar F, Assadi M, Seyedabadi M (2020) The effects of carvedilol, metoprolol and propranolol on cisplatin-induced kidney injury. Drug Chem Toxicol 1\u20137https:\/\/doi.org\/10.1080\/01480545.2020.1846551","DOI":"10.1080\/01480545.2020.1846551"},{"key":"2130_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/pgm.2012.03.2532","volume":"124","author":"H Fares","year":"2012","unstructured":"Fares H, Lavie CJ, Ventura HO (2012) Vasodilating versus first-generation \u03b2-blockers for cardiovascular protection. Postgrad Med 124:7\u201315. https:\/\/doi.org\/10.3810\/pgm.2012.03.2532","journal-title":"Postgrad Med"},{"key":"2130_CR15","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1038\/emboj.2011.248","volume":"30","author":"X Feng","year":"2011","unstructured":"Feng X, Liu X, Zhang W, Xiao W (2011) p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death. EMBO J 30:3397\u20133415. https:\/\/doi.org\/10.1038\/emboj.2011.248","journal-title":"EMBO J"},{"key":"2130_CR16","doi-asserted-by":"publisher","unstructured":"Fernandes-Charpiot\u00a0IMM,Caldas HC,\u00a0Mendes\u00a0GEF,Gomes de S\u00e1 Neto\u00a0L, Oliveira\u00a0HL, Baptista\u00a0MSF,Abbud-Filho\u00a0M (2016) (2016) Validation of an Experimental Model to Study Less Severe Chronic Renal Failure. J Investig Surg\u00a029(5):309\u2013315. https:\/\/doi.org\/10.3109\/08941939.2015.1114689","DOI":"10.3109\/08941939.2015.1114689"},{"key":"2130_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (2017) The PI3K pathway in human disease. Cell 170:605\u2013635. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029","journal-title":"Cell"},{"key":"2130_CR18","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031","journal-title":"N Engl J Med"},{"key":"2130_CR19","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","volume":"35","author":"M Gori","year":"2014","unstructured":"Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Claggett B, Shah AM, Santos ABS, Zile MR, Voors AA, McMurray JJV, Packer M, Bransford T, Lefkowitz M, Solomon SD (2014) Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 35:3442\u20133451. https:\/\/doi.org\/10.1093\/eurheartj\/ehu254","journal-title":"Eur Heart J"},{"key":"2130_CR20","unstructured":"Gounden V, Bhatt H, Jialal I (2021) Renal function tests. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507821\/. Accessed 13 June 2021"},{"key":"2130_CR21","doi-asserted-by":"publisher","unstructured":"Hamzaoui\u00a0M,\u00a0Djerada Z,\u00a0Brunel V, Mulder\u00a0P,\u00a0 Richard V,\u00a0 Bellien\u00a0J,Guerrot\u00a0D (2020) 5\/6 nephrectomy induces different renal cardiac and vascular consequences in 129\/Sv and C57BL\/6JRj mice. Scientific Reports 10(1). https:\/\/doi.org\/10.1038\/s41598-020-58393-w","DOI":"10.1038\/s41598-020-58393-w"},{"key":"2130_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11897-012-0122-8","volume":"10","author":"N Hawwa","year":"2013","unstructured":"Hawwa N, Schreiber MJ, Tang WHW (2013) Pharmacologic management of chronic reno-cardiac syndrome. Curr Heart Fail Rep 10:54\u201362. https:\/\/doi.org\/10.1007\/s11897-012-0122-8","journal-title":"Curr Heart Fail Rep"},{"key":"2130_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1186\/s12885-019-6254-4","volume":"19","author":"F Hong","year":"2019","unstructured":"Hong F, Zhang Y, Cheng W, Sun X, Wang J (2019) \u03b2-arrestin-2 up-regulates toll-like receptor 2 signaling and inhibits apoptosis in human endometrial cancer heterotransplants in nude mice. BMC Cancer 19:1035. https:\/\/doi.org\/10.1186\/s12885-019-6254-4","journal-title":"BMC Cancer"},{"key":"2130_CR24","doi-asserted-by":"publisher","first-page":"e002528","DOI":"10.1161\/CIRCHEARTFAILURE.115.002528","volume":"9","author":"NE Ibrahim","year":"2016","unstructured":"Ibrahim NE, Gaggin HK, Konstam MA, Januzzi JL (2016) Established and emerging roles of biomarkers in heart failure clinical trials. Circ Hear Fail 9:e002528. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002528","journal-title":"Circ Hear Fail"},{"key":"2130_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","volume":"123","author":"NE Ibrahim","year":"2018","unstructured":"Ibrahim NE, Januzzi JL (2018) Established and emerging roles of biomarkers in heart failure. Circ Res 123:614\u2013629. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312706","journal-title":"Circ Res"},{"key":"2130_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/1074248420905683","volume":"25","author":"WS Ibrahim","year":"2020","unstructured":"Ibrahim WS, Ibrahim IAAE-H, Mahmoud MF, Mahmoud AAA (2020) Carvedilol diminishes cardiac remodeling induced by high-fructose\/high-fat diet in mice via enhancing cardiac \u03b2-arrestin2 signaling. J Cardiovasc Pharmacol Ther 25:354\u2013363. https:\/\/doi.org\/10.1177\/1074248420905683","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2130_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cmet.2012.03.005","volume":"15","author":"FR Jornayvaz","year":"2012","unstructured":"Jornayvaz FR, Shulman GI (2012) Diacylglycerol activation of protein kinase C\u03b5 and hepatic insulin resistance. Cell Metab 15:574\u2013584. https:\/\/doi.org\/10.1016\/j.cmet.2012.03.005","journal-title":"Cell Metab"},{"key":"2130_CR28","doi-asserted-by":"publisher","first-page":"14555","DOI":"10.1073\/pnas.0804745105","volume":"105","author":"I-M Kim","year":"2008","unstructured":"Kim I-M, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA (2008) \u03b2-Blockers alprenolol and carvedilol stimulate -arrestin-mediated EGFR transactivation. Proc Natl Acad Sci 105:14555\u201314560. https:\/\/doi.org\/10.1073\/pnas.0804745105","journal-title":"Proc Natl Acad Sci"},{"key":"2130_CR29","doi-asserted-by":"publisher","first-page":"12435","DOI":"10.1073\/pnas.1920310117","volume":"117","author":"J Kim","year":"2020","unstructured":"Kim J, Grotegut CA, Wisler JW, Mao L, Rosenberg PB, Rockman HA, Lefkowitz RJ (2020) The \u03b2-arrestin-biased \u03b2-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. Proc Natl Acad Sci 117:12435\u201312443. https:\/\/doi.org\/10.1073\/pnas.1920310117","journal-title":"Proc Natl Acad Sci"},{"key":"2130_CR30","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/ndt\/gft065","volume":"28","author":"CP Kovesdy","year":"2013","unstructured":"Kovesdy CP, Quarles LD (2013) Fibroblast growth factor-23: what we know, what we don\u2019t know, and what we need to know. Nephrol Dial Transplant 28:2228\u20132236. https:\/\/doi.org\/10.1093\/ndt\/gft065","journal-title":"Nephrol Dial Transplant"},{"key":"2130_CR31","doi-asserted-by":"publisher","first-page":"F1168","DOI":"10.1152\/ajprenal.00606.2015","volume":"310","author":"CP Kovesdy","year":"2016","unstructured":"Kovesdy CP, Quarles LD (2016) FGF23 from bench to bedside. Am J Physiol Physiol 310:F1168\u2013F1174. https:\/\/doi.org\/10.1152\/ajprenal.00606.2015","journal-title":"Am J Physiol Physiol"},{"key":"2130_CR32","doi-asserted-by":"publisher","first-page":"119692","DOI":"10.1016\/j.lfs.2021.119692","volume":"280","author":"Y Li","year":"2021","unstructured":"Li Y, Kang L, Rong K, Zhang Y, Suo Y, Yuan M, Bao Q, Shao S, Tse G, Li R, Liu T, Li G (2021) Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome. Life Sci 280:119692. https:\/\/doi.org\/10.1016\/j.lfs.2021.119692","journal-title":"Life Sci"},{"key":"2130_CR33","doi-asserted-by":"publisher","first-page":"e0116155","DOI":"10.1371\/journal.pone.0116155","volume":"10","author":"L-L Lin","year":"2015","unstructured":"Lin L-L, Wang D, Wang W, Cheng Y-Q, Su D-F, Liu A-J (2015) Long-term treatment of clonidine, atenolol, amlodipine and dihydrochlorothiazide, but not enalapril, impairs the sexual function in male spontaneously hypertensive rats. PLoS ONE 10:e0116155. https:\/\/doi.org\/10.1371\/journal.pone.0116155","journal-title":"PLoS ONE"},{"key":"2130_CR34","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912\u20131934. https:\/\/doi.org\/10.1126\/science.1075762 ((80- ))","journal-title":"Science"},{"key":"2130_CR35","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3389\/fcell.2021.687489","volume":"9","author":"ESF Matthees","year":"2021","unstructured":"Matthees ESF, Haider RS, Hoffmann C, Drube J (2021) Differential regulation of GPCRs\u2014are GRK expression levels the key? Front Cell Dev Biol 9:1303. https:\/\/doi.org\/10.3389\/fcell.2021.687489","journal-title":"Front Cell Dev Biol"},{"key":"2130_CR36","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/HYPERTENSIONAHA.117.09817","volume":"70","author":"KA McCrink","year":"2017","unstructured":"McCrink KA, Maning J, Vu A, Jafferjee M, Marrero C, Brill A, Bathgate-Siryk A, Dabul S, Koch WJ, Lymperopoulos A (2017) \u03b2-Arrestin2 improves post\u2013myocardial infarction heart failure via sarco(endo)plasmic reticulum Ca 2+-ATPase\u2013dependent positive inotropy in cardiomyocytes. Hypertension 70:972\u2013981. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09817","journal-title":"Hypertension"},{"key":"2130_CR37","doi-asserted-by":"publisher","first-page":"H1808","DOI":"10.1152\/ajpheart.00771.2015","volume":"310","author":"RMSM Mohamed","year":"2016","unstructured":"Mohamed RMSM, Morimoto S, Ibrahim IAAE-H, Zhan D-Y, Du C-K, Arioka M, Yoshihara T, Takahashi-Yanaga F, Sasaguri T (2016) GSK-3\u03b2 heterozygous knockout is cardioprotective in a knockin mouse model of familial dilated cardiomyopathy. Am J Physiol Circ Physiol 310:H1808\u2013H1815. https:\/\/doi.org\/10.1152\/ajpheart.00771.2015","journal-title":"Am J Physiol Circ Physiol"},{"key":"2130_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1126\/science.1134562","volume":"315","author":"CD Nelson","year":"2007","unstructured":"Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ (2007) Targeting of diacylglycerol degradation to M1 muscarinic receptors by \u03b2-arrestins. Science 315:663\u2013666. https:\/\/doi.org\/10.1126\/science.1134562 ((80- ))","journal-title":"Science"},{"key":"2130_CR39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.yjmcc.2010.11.005","volume":"51","author":"N Noor","year":"2011","unstructured":"Noor N, Patel CB, Rockman HA (2011) \u03b2-Arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol 51:534\u2013541. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.11.005","journal-title":"J Mol Cell Cardiol"},{"key":"2130_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2021.03.035","volume":"88","author":"S Paolillo","year":"2021","unstructured":"Paolillo S, Dell\u2019Aversana S, Esposito I, Poccia A, Perrone Filardi P (2021) The use of \u03b2-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues. Eur J Intern Med 88:9\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2021.03.035","journal-title":"Eur J Intern Med"},{"key":"2130_CR41","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1681\/ASN.2012020145","volume":"23","author":"M Park","year":"2012","unstructured":"Park M, Hsu C, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG (2012) Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 23:1725\u20131734. https:\/\/doi.org\/10.1681\/ASN.2012020145","journal-title":"J Am Soc Nephrol"},{"key":"2130_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jacbts.2018.06.002","volume":"3","author":"M Park","year":"2018","unstructured":"Park M, Steinberg SF (2018) Carvedilol prevents redox inactivation of cardiomyocyte \u03b21-adrenergic receptors. JACC Basic to Transl Sci 3:521\u2013532. https:\/\/doi.org\/10.1016\/j.jacbts.2018.06.002","journal-title":"JACC Basic to Transl Sci"},{"key":"2130_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/938651","volume":"2011","author":"P Pateinakis","year":"2011","unstructured":"Pateinakis P, Papagianni A (2011) Cardiorenal syndrome type 4\u2014cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. Int J Nephrol 2011:1\u20138. https:\/\/doi.org\/10.4061\/2011\/938651","journal-title":"Int J Nephrol"},{"key":"2130_CR44","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA (2019) Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment Strategies: a scientific statement from the American Heart Association. Circulation 139:e840\u2013e878. https:\/\/doi.org\/10.1161\/CIR.0000000000000664","journal-title":"Circulation"},{"key":"2130_CR45","unstructured":"Rehman B, Sanchez DP, Shah S (2021) Atenolol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539844\/. Accessed 9 June 2021"},{"key":"2130_CR46","first-page":"336","volume":"283","author":"JC Rodriguez-Perez","year":"1997","unstructured":"Rodriguez-Perez JC, Losada A, Anabitarte A, Cabrera J, Llobet J, Palop L, Plaza C (1997) Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther 283:336\u2013344","journal-title":"J Pharmacol Exp Ther"},{"key":"2130_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.ackd.2018.08.004","volume":"25","author":"C Ronco","year":"2018","unstructured":"Ronco C, Bellasi A, Di Lullo L (2018) Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis 25:382\u2013390. https:\/\/doi.org\/10.1053\/j.ackd.2018.08.004","journal-title":"Adv Chronic Kidney Dis"},{"key":"2130_CR48","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527\u20131539. https:\/\/doi.org\/10.1016\/j.jacc.2008.07.051","journal-title":"J Am Coll Cardiol"},{"key":"2130_CR49","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","volume":"31","author":"C Ronco","year":"2010","unstructured":"Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P (2010) Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 31:703\u2013711. https:\/\/doi.org\/10.1093\/eurheartj\/ehp507","journal-title":"Eur Heart J"},{"key":"2130_CR50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/biom11020218","volume":"11","author":"M Seyedabadi","year":"2021","unstructured":"Seyedabadi M, Gharghabi M, Gurevich EV, Gurevich VV (2021) Receptor-Arrestin Interactions: the GPCR Perspective. Biomolecules 11:218. https:\/\/doi.org\/10.3390\/biom11020218","journal-title":"Biomolecules"},{"key":"2130_CR51","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbabio.2007.01.023","volume":"1767","author":"P Sgobbo","year":"2007","unstructured":"Sgobbo P, Pacelli C, Grattagliano I, Villani G, Cocco T (2007) Carvedilol inhibits mitochondrial complex I and induces resistance to H2O2-mediated oxidative insult in H9C2 myocardial cells. Biochim Biophys Acta - Bioenerg 1767:222\u2013232. https:\/\/doi.org\/10.1016\/j.bbabio.2007.01.023","journal-title":"Biochim Biophys Acta - Bioenerg"},{"key":"2130_CR52","doi-asserted-by":"publisher","first-page":"252","DOI":"10.14348\/molcells.2019.2440","volume":"42","author":"J-I Shin","year":"2019","unstructured":"Shin J-I, Jeon Y-J, Lee S, Lee YG, Kim JB, Lee K (2019) G-protein-coupled receptor 120 mediates DHA-induced apoptosis by regulating IP3R, ROS and ER stress levels in cisplatin-resistant cancer cells. Mol Cells 42:252\u2013261. https:\/\/doi.org\/10.14348\/molcells.2019.2440","journal-title":"Mol Cells"},{"key":"2130_CR53","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000493037","volume":"49","author":"H-P Song","year":"2018","unstructured":"Song H-P, Chu Z-G, Zhang D-X, Dang Y-M, Zhang Q (2018) PI3K\u2013AKT pathway protects cardiomyocytes against hypoxia-induced apoptosis by MitoKATP-mediated mitochondrial translocation of pAKT. Cell Physiol Biochem 49:717\u2013727. https:\/\/doi.org\/10.1159\/000493037","journal-title":"Cell Physiol Biochem"},{"key":"2130_CR54","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1258\/ebm.2012.012045","volume":"237","author":"J \u0160v\u00edglerov\u00e1","year":"2012","unstructured":"\u0160v\u00edglerov\u00e1 J, Kuncov\u00e1 J, Nalos L, Holas J, Tonar Z, Rajdl D, \u0160tengl M (2012) Cardiac remodeling in rats with renal failure shows interventricular differences. Exp Biol Med 237:1056\u20131067. https:\/\/doi.org\/10.1258\/ebm.2012.012045","journal-title":"Exp Biol Med"},{"key":"2130_CR55","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.33549\/physiolres.932003","volume":"59","author":"J \u0160v\u00edglerov\u00e1","year":"2010","unstructured":"\u0160v\u00edglerov\u00e1 J, Kuncov\u00e1 J, Nalos L, Tonar Z, Rajdl D, \u0160tengl M (2010) Cardiovascular parameters in rat model of chronic renal failure induced by subtotal nephrectomy. Physiol Res 59:S81\u2013S88. https:\/\/doi.org\/10.33549\/physiolres.932003","journal-title":"Physiol Res"},{"key":"2130_CR56","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","volume":"18","author":"JM Ter Maaten","year":"2016","unstructured":"Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CSP, Navis G, Voors AA (2016) Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18:588\u2013598. https:\/\/doi.org\/10.1002\/ejhf.497","journal-title":"Eur J Heart Fail"},{"key":"2130_CR57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/01.RES.74.2.206","volume":"74","author":"M Ungerer","year":"1994","unstructured":"Ungerer M, Parruti G, B\u00f6hm M, Puzicha M, DeBlasi A, Erdmann E, Lohse MJ (1994) Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res 74:206\u2013213. https:\/\/doi.org\/10.1161\/01.RES.74.2.206","journal-title":"Circ Res"},{"key":"2130_CR58","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3389\/fphar.2018.01369","volume":"9","author":"J van Gastel","year":"2018","unstructured":"van Gastel J, Hendrickx JO, Leysen H, Santos-Otte P, Luttrell LM, Martin B, Maudsley S (2018) \u03b2-arrestin based receptor signaling paradigms: potential therapeutic targets for complex age-related disorders. Front Pharmacol 9:1369. https:\/\/doi.org\/10.3389\/fphar.2018.01369","journal-title":"Front Pharmacol"},{"key":"2130_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3810\/pgm.2009.05.2007","volume":"121","author":"MR Weir","year":"2009","unstructured":"Weir MR (2009) \u03b2-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med 121:90\u201398. https:\/\/doi.org\/10.3810\/pgm.2009.05.2007","journal-title":"Postgrad Med"},{"key":"2130_CR60","doi-asserted-by":"publisher","first-page":"16657","DOI":"10.1073\/pnas.0707936104","volume":"104","author":"JW Wisler","year":"2007","unstructured":"Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci 104:16657\u201316662. https:\/\/doi.org\/10.1073\/pnas.0707936104","journal-title":"Proc Natl Acad Sci"},{"key":"2130_CR61","doi-asserted-by":"publisher","unstructured":"Zhang\u00a0Y,\u00a0Kompa\u00a0AR (2014) A practical guide to subtotal nephrectomy in the rat with subsequent methodology for assessing renal and cardiac function. Nephrol.19(9):552\u2013561. https:\/\/doi.org\/10.1111\/nep.12279","DOI":"10.1111\/nep.12279"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-021-02130-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T10:21:53Z","timestamp":1633083713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-021-02130-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1007\/s00210-021-02130-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animals received humane care in compliance with the Animal Care Guidelines of the National Institutes of Health (NIH), and the Research Ethics Committee of the Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, approved the design of the experiment (approval number P4-8\u20132017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the manuscript to be published in its final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}